Why combustion and vaporization are not the same chemical process
The first correction is simple and important: smoking cannabis and vaporizing cannabis are not two versions of the same event. Smoking creates smoke by burning plant material. Vaporization heats cannabis below ignition so that cannabinoids, terpenes, and other volatile compounds leave the plant and enter the air as an aerosol. That distinction sounds technical, but it is the whole argument. If the material burns, the chemistry shifts sharply toward combustion products. If it does not burn, the aerosol profile changes.
A few terms matter here. Pyrolysis is thermal decomposition caused by heat, often with limited oxygen; molecules break apart before or during burning. Combustion is oxidative burning, the exothermic reaction that produces flame or glowing char and generates new compounds such as carbon monoxide and soot. An aerosol is a suspension of tiny liquid droplets and/or solid particles in a gas. Tar is the sticky particulate residue in smoke, made up of condensed hydrocarbons, phenols, and many byproducts of incomplete combustion. Sidestream loss is the material lost from the burning tip between puffs; with a lit joint, cannabinoids and toxicants are released even when nobody is inhaling.
That is why “vapor is just smoke without the smell” is wrong. It is also why “vaporization is safe because nothing harmful forms” is too glib. The real question is not branding language. It is chemistry at a given temperature.
Pyrolysis, oxidation, and aerosolization are different events
Cannabis contains compounds that can volatilize before the plant catches fire. Delta-9-THC, CBD, and many terpenes can transfer into inhalable aerosol at temperatures well below the point where dried plant matter sustains combustion. In controlled laboratory conditions, this is exactly what vaporizers are trying to do: heat enough to release target compounds, not enough to set off broad oxidative breakdown.
But “below combustion” does not mean “no chemistry happens.” Heat still changes molecules. Some cannabinoids and terpenes evaporate or distill into the airflow; some partially degrade; some remain in the plant. As temperature rises, aerosol density increases, extraction becomes more complete, and degradation also increases. That is why the chemistry of a 170°C session is not the chemistry of a 230°C session, even in the same device.
The published literature supports this temperature-dependent story. Gieringer, St. Laurent, and Goodrich (2004) found that cannabis vapor contained cannabinoids with far fewer pyrolytic compounds than smoke. Pomahacova, Van der Kooy, and Verpoorte (2009) showed substantial cannabinoid recovery under controlled vaporization conditions, while compounds such as benzene, toluene, and naphthalene appeared mainly at the highest settings tested. Combustion is not “hotter vaporization.” It is a different regime, where oxidation and pyrolysis dominate.
What smoke contains that vapor aims to avoid
When organic plant matter burns, it creates a chemically messy mixture. Cannabis smoke contains cannabinoids, yes, but also carbon monoxide, polycyclic aromatic hydrocarbons (PAHs), volatile organic compounds, tar, fine particles, and other irritants formed during incomplete combustion. Many of these are not there because cannabis is unusual; they are there because burning biomass produces them.
PAHs matter because they are classic combustion products formed when carbon-rich material is heated hard enough to crack and recombine into fused aromatic rings. Carbon monoxide matters because it is generated when carbon-containing material burns without complete oxidation to carbon dioxide. Tar matters because it carries particulate and condensed organic residues deep into the airways. Sidestream loss matters because a burning joint continues to emit both cannabinoids and combustion byproducts between inhalations, which changes dose efficiency and exposure.
Clinical work lines up with the chemistry. In the Abrams et al. randomized crossover trial at UCSF and California Pacific Medical Center, published in Clinical Pharmacology & Therapeutics in 2007, 18 healthy users received smoked and vaporized cannabis under matched THC conditions. Plasma THC exposure and subjective effects were broadly comparable, but exhaled carbon monoxide rose far less with vaporization than with smoking. That finding is hard to dismiss, because carbon monoxide is a direct marker of combustion exposure. Respiratory data also point in the same direction: Earleywine and Barnwell (2007), using a dataset of 6,883 users, reported fewer respiratory symptoms among vaporizer users, and Van Dam and Earleywine (2010) found symptom reductions after switching away from smoking.
Why the phrase “no carbon monoxide” needs careful wording
“Vaporization produces no carbon monoxide” is the kind of sentence that sounds tidy and can still mislead. The defensible version is narrower: at correct vaporization temperatures, and in well-controlled conditions, carbon monoxide is absent or greatly reduced relative to smoke. That is not the same as an absolute promise across every device, load, and user behavior.
Why the caution? Because real devices are imperfect. Heating chambers can develop local hot spots. Poor temperature control can char plant material at the surface even when the displayed temperature looks moderate. Concentrate hardware can overheat oils on a coil. Contaminants or additives can decompose into unwanted byproducts. Once material is scorched or partially burned, the chemistry starts moving back toward pyrolysis and oxidation.
The same caution applies to PAHs. Lower is not the same as zero in every circumstance. Evidence supports marked reductions compared with smoke, not magical elimination under all conditions. That evidence-first framing matters later in this article, especially when dry-herb vaporization is confused with cartridge aerosols implicated in the EVALI outbreak. Blount et al. in the New England Journal of Medicine (2020) linked vitamin E acetate in bronchoalveolar-lavage fluid to many EVALI cases; that was a contaminant story centered on illicit oil products, not proof that all cannabis aerosolization behaves like smoke.
So the chemically honest position is this: combustion creates smoke by burning cannabis, while vaporization aims to generate an aerosol without burning it. That shift removes or sharply lowers many combustion products, including carbon monoxide and many PAHs, when temperatures stay below pyrolytic conditions. It does not make inhalation harmless. It does make the chemistry meaningfully different.
References: Abrams et al., 2007, Clin Pharmacol Ther (https://pubmed.ncbi.nlm.nih.gov/17429350/); Gieringer et al., 2004, J Cannabis Ther; Pomahacova et al., 2009, Int J Pharm; Earleywine & Barnwell, 2007 (https://pubmed.ncbi.nlm.nih.gov/17643789/); Van Dam & Earleywine, 2010 (https://harmreductionjournal.biomedcentral.com/articles/10.1186/1477-7517-7-11); Blount et al., 2020, N Engl J Med (https://www.nejm.org/doi/full/10.1056/NEJMoa1916433).
What actually changes chemically when cannabis is vaporized
The chemical shift from smoking to vaporizing is real, but it is often described too loosely. A dry-herb vaporizer does not create a cloud of pure THC floating in air. The inhaled plume is an aerosol: tiny liquid and semi-liquid droplets plus gases, carrying cannabinoids, terpenes, water, and a variable amount of thermal breakdown products. What changes is the balance of compounds produced when cannabis is heated below overt combustion rather than ignited.
That distinction matters. Smoke comes from pyrolysis and oxidation of plant matter. Vaporization, when temperature is controlled, is aerosol generation without sustained burning. Those are different chemical regimes, not just different gadget categories.
Analytical work supports that difference. Gieringer, St. Laurent, and Goodrich compared cannabis smoke with vapor generated by a vaporizer and found that the vapor fraction was enriched in cannabinoids relative to pyrolytic byproducts seen in smoke, with much lower levels of toxic combustion products overall (Journal of Cannabis Therapeutics, 2004). Pomahacova, Van der Kooy, and Verpoorte later showed that controlled vaporization could recover substantial cannabinoids while keeping benzene, toluene, and naphthalene low or undetectable at lower settings, with those compounds becoming more detectable as temperatures climbed toward the upper end tested (International Journal of Pharmaceutics, 2009). The chemistry is therefore temperature-dependent, not binary.
Cannabinoid release versus thermal degradation
Heating cannabis does two competing things at once. It releases desired compounds from the plant matrix, and it also starts to alter them.
One of the first important changes is decarboxylation. In raw cannabis flower, much of the THC exists as tetrahydrocannabinolic acid, THCA. THCA is not the same molecule as THC; it carries an extra carboxyl group. Heat removes that group as carbon dioxide, converting THCA into delta-9-THC. The same general principle applies to CBDA converting to CBD. This is one reason heating matters even before any visible smoke appears. Without enough heat and time, cannabinoid acids are only partly converted, and psychoactive THC delivery is lower.
After decarboxylation, cannabinoids and terpenes can transfer into the aerosol phase, but the old “boiling point list” framing is too neat for real cannabis. In a plant matrix, release depends on pressure, moisture, grind, resin distribution, airflow, and how long the material sits at a given temperature. Some compounds begin to volatilize across a range rather than at one sharp point. Some decompose near or before their nominal boiling temperatures. So it is better to talk about approximate release ranges than exact boiling points.
As temperature rises, extraction generally becomes more complete. More THC, CBD, and less volatile constituents can enter the aerosol. Yet the gains come with tradeoffs. Terpenes that contribute aroma and flavor are often more volatile and more chemically fragile than cannabinoids. They may be released early, then depleted or degraded as heating continues. Oxidation products and other breakdown compounds also increase with hotter, longer sessions.
THC itself is not chemically immortal. Under stronger heat and oxygen exposure, it can degrade to cannabinol-related products and other oxidized or rearranged compounds. At still higher temperatures, the plant matrix begins to char. That is the point where the practical distinction between “vapor” and “smoke” starts to blur. A session can begin as vaporization and drift toward low-level pyrolysis if the load is overheated, poorly mixed, or held too long against a hot surface.
This is why a visible brown, then dark brown, then black progression in spent herb is not just cosmetic. Pale to medium brown usually suggests dehydration, decarboxylation, and extraction. Blackened spots suggest local overheating. Local overheating is chemistry, not aesthetics.
Polycyclic aromatic hydrocarbons, carbon monoxide, and carbonyl compounds
The strongest chemistry-based case for dry-herb vaporization is the reduction in classic combustion toxicants. When cannabis is smoked, the burning tip reaches temperatures high enough for extensive pyrolysis and incomplete combustion. That generates carbon monoxide, tar, soot, polycyclic aromatic hydrocarbons (PAHs), and a long list of volatile irritants.
When cannabis is vaporized at controlled temperatures below ignition, those products fall sharply. Abrams et al. ran a randomized crossover clinical study in 18 adults and found that vaporized cannabis delivered plasma THC and subjective effects comparable to smoking, while exhaled carbon monoxide rose far less with vaporization than with smoking (Clinical Pharmacology & Therapeutics, 2007). That is one of the clearest human markers showing less combustion exposure.
Laboratory chemistry aligns with the clinical result. Gieringer et al. reported fewer pyrolytic compounds in vapor than smoke. Pomahacova et al. found that at 210°C, cannabinoids could be efficiently transferred, while toxic aromatic compounds such as benzene and naphthalene remained low and were mainly a concern at the highest temperature conditions tested. Put plainly: lower-temperature controlled heating changes the plume away from smoke chemistry and toward cannabinoid-rich aerosol chemistry.
But “no PAHs” or “no carbon monoxide” needs care. At correct temperatures in a well-functioning dry-herb vaporizer, PAHs and carbon monoxide are absent or greatly reduced relative to smoke. That is defensible. Zero under every real-world condition is not. If herb touches an excessively hot surface, if a device overshoots its set point, if airflow is restricted, or if a user continues heating a nearly exhausted load until it chars, then local combustion-like chemistry can occur. Small hot spots can produce carbonyls, aromatics, and combustion markers even when the display still says “vape temperature.”
Carbonyl compounds deserve separate mention. Formaldehyde, acetaldehyde, and acrolein are often discussed in e-cigarette research, but the principle carries over: organic material heated hard enough can fragment into reactive aldehydes and ketones. Dry herb does not behave like propylene glycol or glycerol liquids, yet it still contains carbohydrates, terpenes, lipids, and other precursors that can break down thermally. So the chemical story is not that vaporization eliminates byproducts. It changes their quantity and profile, usually downward relative to smoke, until overheating pushes them back up.
Why matrix, airflow, and temperature stability matter
Cannabis is not a pure chemical on a hot plate. It is a wet, resinous, fibrous plant matrix. That matrix controls what actually reaches the lungs.
Start with the herb itself. Moisture content changes heat transfer. Very dry flower heats faster and can char more easily. Coarser grind allows more airflow but may extract less evenly. Finer grind increases surface area and can improve transfer, but it can also pack too densely, restricting air movement and creating hot spots. Resin-rich material may aerosolize differently from leafier material because cannabinoids and terpenes are concentrated unevenly across the load.
Airflow matters just as much. In convection-heavy designs, incoming hot air strips volatile compounds from the plant surface and carries them into the aerosol stream. If airflow is too weak, the load may cook in place and overheat locally. If airflow is too forceful, the chamber may cool, reducing extraction or making aerosol generation inconsistent. In conduction-dominant designs, direct contact with hot chamber walls can create steep temperature gradients. The herb touching the surface may become much hotter than herb in the center. That increases the risk of partial charring even when the average chamber temperature appears moderate.
Temperature stability is where device quality really becomes a chemistry issue. A set point is not the same thing as actual herb temperature. Portable units with limited power reserves may sag during a draw, then overshoot while recovering. Desktop systems often hold airflow temperature more steadily. Poor control can push a load through repeated cycles of underheating and overheating, which gives neither clean low-temperature terpene preservation nor efficient high-temperature extraction. It gives inconsistency.
This is why all vaporizers cannot be treated as chemically equivalent. The same flower at the same nominal temperature can produce different aerosols depending on chamber geometry, sensor placement, heating mode, draw speed, and session length. Lanz, Mattsson, Soydaner, and Brenneisen showed in 2016 that vapor and smoke composition vary substantially with conditions, including terpene and cannabinoid transfer patterns (Journal of Pharmaceutical and Biomedical Analysis).
So what actually changes chemically when cannabis is vaporized? The answer is not “everything becomes harmless vapor,” and it is not “nothing changes unless it burns.” Controlled heating shifts the aerosol away from smoke toxicants and toward cannabinoids, terpenes, water, and lower levels of thermal degradation products. As temperatures rise, that advantage narrows. Once local charring begins, the chemistry starts moving back toward smoke. That is the line that matters: not marketing language, but whether the device keeps the plant below meaningful pyrolysis while still releasing the compounds the user is trying to inhale.
Sources: Gieringer et al., 2004; Abrams et al., 2007, https://pubmed.ncbi.nlm.nih.gov/17429350/ ; Pomahacova et al., 2009; Lanz et al., 2016.
Approximate boiling and release temperatures of major cannabinoids and terpenes
“THC boils at X°C” looks tidy in a chart. Real cannabis chemistry is not tidy.
Inside a vaporizer chamber, cannabinoids and terpenes are not sitting as isolated pure liquids at standard pressure. They are embedded in a plant matrix, mixed with waxes, water, acids, and other volatiles, then heated unevenly while air moves through the load. That means the temperatures at which compounds begin to evaporate, transfer into aerosol, oxidize, or decompose are only approximate. A value reported in a handbook for a purified compound under vacuum is not a universal number for ground flower in a real device.
This distinction matters because many popular “boiling point” charts overpromise precision they do not have. What users actually notice is broader and more useful: lower-temperature draws tend to favor the most volatile aroma compounds first, while higher settings generally increase total cannabinoid extraction and aerosol density. At the same time, pushing temperature upward also raises the chance of terpene loss, harsher vapor, and thermal degradation products. Studies of cannabis vaporization support that temperature-dependent story far better than simplistic one-number charts do. Laboratory work by Gieringer, St. Laurent, and Goodrich (2004), Pomahacova, Van der Kooy, and Verpoorte (2009), and Lanz et al. (2016) all point to the same pattern: controlled heating can transfer cannabinoids effectively without the full pyrolytic chemistry of smoke, but the aerosol composition still shifts as temperature rises. Sources: Gieringer et al., 2004, Journal of Cannabis Therapeutics; Pomahacova et al., 2009, International Journal of Pharmaceutics; Lanz et al., 2016, Journal of Pharmaceutical and Biomedical Analysis.
Why “boiling point” charts are oversold
A boiling point is a property measured under defined conditions. Cannabis vaporization is a process, not a single-condition textbook experiment. Three complications matter most.
First, pressure changes the number. Some cannabinoid boiling values often repeated online come from reduced-pressure measurements, not atmospheric pressure. Second, plant matrices change release behavior. A terpene can begin leaving flower well below its listed pure-compound boiling point because it is diffusing out of resin, co-evaporating with other compounds, and being stripped by passing hot air. Third, decomposition can begin near, below, or instead of a clean boiling event. Cannabinoids and terpenes are heat-sensitive. They do not always wait politely to boil before changing chemically.
That is why “release temperature,” “volatilization range,” or “transfer range” is better language than pretending every molecule flips into vapor at one exact temperature. Decarboxylation adds another layer: in raw cannabis, much of the THC and CBD content starts as THCA and CBDA, which must lose a carboxyl group through heating before large amounts of neutral THC or CBD are available for inhalation. So a user setting a device to 160–180°C is not just chasing a cannabinoid’s nominal boiling point; they are also affecting decarboxylation rate, airflow-driven extraction, and degradation risk.
Temperature table for cannabinoids
The table below uses approximate values reported in chemistry references and cannabis vaporization literature. These should be read as rough volatilization or release-relevant temperatures, not exact universal thresholds.
| Cannabinoid | Approximate boiling / release temperature | Notes | |---|---:|---| | Δ9-THC | ~155–157°C | Commonly cited for purified THC under specific conditions; meaningful aerosol transfer can occur across a broader range in flower. | | CBD | ~160–180°C | Reported values vary widely by method and pressure; some sources place it higher under reduced-pressure conditions. | | CBN | ~185°C | Less abundant in fresh flower; often associated with aged or oxidized material. | | CBC | ~220°C | Frequently cited, but literature support is thinner and conditions vary. Treat as especially approximate. | | THCA | does not simply “boil”; decarboxylates with heat before/while volatilization products appear | Raw acidic cannabinoid; heating converts it toward THC. | | CBDA | does not simply “boil”; decarboxylates with heat before/while volatilization products appear | Raw acidic cannabinoid; heating converts it toward CBD. |
A practical reading of this table is more useful than a literal one. Around the mid- to upper-100s °C, many users report lighter, more aromatic draws because volatile terpenes and some THC are readily transferred. Raise the temperature and extraction becomes more complete. More CBD, CBN, and less-volatile fractions enter the aerosol, especially over repeated draws. But there is no hard line where THC appears at 157°C and CBD waits obediently until 180°C. Real devices overlap.
Pomahacova et al. (2009) found substantial cannabinoid recovery at 210°C under controlled vaporization conditions, while signs of aromatic toxicants such as benzene, toluene, and naphthalene emerged only at the highest settings tested. That is exactly why temperature matters: extraction improves with heat, but chemistry gets messier as the margin above ideal vaporization narrows. Source: Pomahacova et al., 2009, https://pubmed.ncbi.nlm.nih.gov/19394103/
Temperature table for major terpenes
Terpenes are even more prone to oversimplified chart culture than cannabinoids. Their aroma impact is obvious, so charts get shared constantly, usually without pressure conditions or decomposition caveats.
| Terpene | Approximate boiling / release temperature | Typical sensory association | |---|---:|---| | β-Myrcene | ~166–168°C | Earthy, musky, herbal | | d-Limonene | ~176°C | Citrus | | α-Pinene | ~155–156°C | Pine, sharp resin | | β-Pinene | ~165°C | Woody pine | | Linalool | ~198°C | Floral, lavender-like | | β-Caryophyllene | ~119–130°C | Peppery, spicy | | Humulene | ~198°C | Woody, hoppy |
These numbers help explain why lower-temperature sessions often taste brighter. β-Caryophyllene and pinene-family compounds are relatively easy to drive off early, so the first draws can carry a lot of aroma before the chamber is fully depleted of cannabinoids. Myrcene and limonene also show up readily in moderate-temperature vapor, contributing the familiar herbal and citrus notes many users associate with fresh flower.
As temperature rises, two things happen at once. Heavier and less readily transferred compounds are extracted more efficiently, which can make effects feel fuller and vapor denser. Flavor usually flattens. Some of the most delicate terpenes are depleted early or degraded by prolonged heat exposure. Lanz et al. (2016) found that both transfer and degradation depend strongly on conditions, reinforcing the point that terpene presence in inhaled aerosol is not predicted by a single boiling number alone. Source: Lanz et al., 2016, https://pubmed.ncbi.nlm.nih.gov/26841835/
So the right way to read temperature charts is modestly. They are directional, not absolute. They explain why low settings preserve more aromatics and why higher settings extract more total cannabinoids. They do not tell you exactly what is in each puff, and they should never be mistaken for a guarantee that a compound appears only above one temperature or remains intact below it.
Heating design matters: conduction, convection, and hybrid systems
The phrase “conduction vs convection” gets treated like branding. It is really an engineering question with chemical consequences. Conduction describes heat moving into cannabis through direct contact with a hot surface or chamber wall. Convection describes heat carried by hot air moving through the packed material. Those are different ways of delivering energy, and they do not produce identical aerosols in practice.
That distinction matters because vaporization is not defined by a product category. It is defined by controlled heating below the point where the plant matrix enters sustained pyrolysis and combustion. If heating is uneven, local parts of the load can run much hotter than the displayed temperature. That is where claims about “clean vapor” start to break down.
Conduction heating and the risk of hot spots
In a conduction-heavy design, the herb sits against a heated oven, capsule, plate, or chamber wall. The cannabis closest to that surface receives the strongest heat flux first. If packing is tight, moisture is uneven, or the load is not stirred, extraction can become patchy: browned material near the wall, greener material in the center.
That unevenness is not just cosmetic. Localized hot spots can drive off volatile terpenes early, then push some areas toward charring while the rest of the load still contains cannabinoids. Terpenes such as beta-caryophyllene, myrcene, and limonene are relatively volatile and can be lost quickly if one part of the chamber overshoots the intended range. Once surface temperatures climb too high, thermal degradation products rise as well. The chemistry starts to move away from controlled aerosol generation and toward pyrolysis.
This is why conduction devices depend heavily on chamber design, sensor placement, and user technique. A stable readout on the display does not guarantee a uniform plant temperature. The sensor may be measuring a heater block rather than the hottest point in the load. Poor temperature control can therefore produce harsher vapor and less repeatable dosing, even when the nominal setting looks reasonable.
Convection heating and airflow-driven extraction
Convection works differently. Heated air passes through the cannabis bed and transfers energy across much more of the material at once. In a well-designed system, this usually means more even extraction and fewer extreme hot spots than direct-surface heating. It can also improve repeatability from one draw to the next, since the active heating occurs during airflow rather than by baking the load between puffs.
That said, convection is not automatically precise. It depends on airflow, thermal mass, and heater recovery. Draw too hard and incoming air may cool the heater or shorten contact time with the plant, reducing extraction. Draw too slowly and the load may continue heating aggressively, raising the risk of terpene loss and irritant formation. Devices with greater thermal mass tend to handle these airflow swings better because the heater temperature drops less during inhalation.
The payoff, when convection is stable, is chemical consistency. Studies comparing smoke with vaporized cannabis found that temperature-controlled vaporization shifts the aerosol toward cannabinoids with fewer pyrolytic byproducts than smoke, but that advantage depends on keeping the process out of combustion territory. Gieringer, St. Laurent, and Goodrich in 2004, and Pomahacova, Van der Kooy, and Verpoorte in 2009, both support the basic pattern: lower pyrolytic contamination under controlled vaporization conditions, with unwanted compounds appearing more readily at hotter settings.
Hybrid behavior in real devices
Most real devices are hybrids whether or not the label says so. A chamber wall heats by contact while incoming air adds convective transfer. The balance changes during use. The first seconds may be conduction-dominant while the oven preheats the load; a long inhalation may shift extraction toward convection; the period between draws may return the chamber to conductive baking.
That is why marketing shorthand can mislead. A “convection” device may still create conductive hot spots at the chamber surface. A “conduction” device may behave more evenly if airflow is well managed and the load is small. What matters is not the badge but the thermal profile across the material.
Chemically, hybrids live or die by control. If they keep temperatures stable across the load, they can preserve more terpenes at lower settings and extract cannabinoids predictably at higher ones. If they do not, hot edges and cooler centers produce mixed results: wasted actives, harsher flavor, and more degradation products. Heating mode is therefore not a lifestyle preference. It is one of the main reasons two vaporizers set to the same temperature can generate noticeably different aerosols.
Dry herb versus concentrate vaporizers
“Vaporizer” is not a single exposure category. Heating ground flower below combustion and heating a concentrated extract on a metal coil can both produce an inhalable aerosol, but the source material, temperature profile, and toxicology are different enough that they should not be lumped together. This matters because many public discussions still use “vaping cannabis” to describe everything from controlled dry-herb convection devices to illicit oil cartridges linked to EVALI. Chemically, that shortcut hides more than it explains.
Dry herb aerosol from plant material
Dry-herb vaporization starts with cannabis flower: a plant matrix containing cannabinoids, terpenes, flavonoids, moisture, cuticular waxes, and whatever remains from cultivation and curing. Even before any device differences are considered, that composition sets the aerosol apart from smoke and apart from concentrate vapor. The material is not a purified cannabinoid source. It is heated plant matter.
When temperature stays below the point of ignition, the aerosol shifts toward volatilized cannabinoids and terpenes with lower levels of pyrolysis products than smoke. That is the core finding behind laboratory comparisons such as Gieringer, St. Laurent, and Goodrich (2004), and controlled vaporization work by Pomahacova, Van der Kooy, and Verpoorte (2009). The chemistry is temperature dependent, not magic. Raise the temperature too far, create hot spots, or char the load, and the profile moves back toward combustion byproducts.
Dry herb still has impurities to think about. Waxes and heavier plant constituents can be entrained into the aerosol. Residues from fertilizers, pesticides, or poor post-harvest handling may also matter if present. Moisture changes extraction behavior as well: a drier load heats faster and can produce harsher aerosol, while a moister load may extract less evenly. Heating style matters here. Conduction devices can create localized hot zones where the herb touching the oven walls gets much hotter than the rest, increasing the chance of browning or partial charring. Convection systems usually heat more evenly, though actual performance depends on airflow, load packing, and temperature control.
That is why dry-herb aerosol is best understood as plant-derived aerosol, not “just THC vapor.” It usually contains many of the same desirable cannabinoids and terpenes sought by users, but also traces of thermally altered plant compounds. The advantage relative to smoking is lower exposure to carbon monoxide and many polycyclic aromatic hydrocarbons when combustion is avoided, not the absence of chemistry.
Concentrate aerosol from extracts and oils
Concentrate devices start from a different feedstock. Instead of intact flower, they heat extracts that may contain very high cannabinoid concentrations, reintroduced terpenes, residual solvents if processing was poor, and in some products extra ingredients that are not native to cannabis at all. That changes the aerosol from the start.
An extract can be relatively simple or chemically messy. Some concentrates are mostly cannabinoids with a reduced terpene fraction because volatile compounds were lost during processing. Others are terpene-heavy because terpenes were added back. Oils in cartridges may include thinning agents or contaminants, especially in illicit products. This is where broad statements about “weed vapes” become scientifically sloppy. A cartridge filled with purified cannabinoids behaves differently from one cut with vitamin E acetate or other diluents, and both differ from a chamber full of flower.
Hardware compounds the problem. Many concentrate systems use exposed coils, ceramic heaters, or small high-energy surfaces that can generate very high localized temperatures even when the nominal device setting looks moderate. Those hot surfaces can degrade solvents, terpenes, and additives into carbonyl compounds, including formaldehyde-related products under some conditions. The point is not that concentrate vaporization always produces high levels of these toxicants. The point is that the risk depends heavily on extract composition and heater behavior, far more than in a simple dry-herb setup.
Why the toxicology questions are different
Dry herb and concentrates share one principle: if material is aerosolized below combustion, exposure to classic smoke toxicants can drop sharply. Abrams et al. (2007) showed that vaporized cannabis delivered THC with effects and plasma exposure similar to smoking, while exhaled carbon monoxide rose far less. That supports vaporization as a lower-combustion route. It does not mean all vaporizers create the same aerosol.
For dry herb, the main toxicology question is usually how much combustion or near-combustion occurs, and how device design affects charring, carbon monoxide, PAHs, and irritant byproducts. For concentrates, the question often shifts to ingredient purity and heater-induced degradation. Is the extract carrying residual butane, ethanol, or pesticides? Are terpenes overheating on a coil? Is there a diluent that should never be inhaled? Those are not side issues. They are central.
This distinction becomes essential when discussing EVALI. The 2019 outbreak was tied primarily to contaminated THC oil cartridges, not to dry-herb vaporization as a category. CDC reported 2,807 hospitalized EVALI cases or deaths by February 18, 2020, with 68 confirmed deaths. In a key study, Blount et al. (2020) detected vitamin E acetate in bronchoalveolar-lavage fluid from 48 of 51 EVALI patients and in none of the healthy comparators. That is a contaminant story. It is not evidence that all cannabis aerosolization methods carry the same hazard.
So “vapes” is too broad to be useful. The right comparison is specific: flower versus extract, clean matrix versus contaminated one, stable heater versus overheating coil, vaporization versus combustion. Without those distinctions, the chemistry gets blurred and the health discussion goes off track.
Sources: Abrams et al., Clinical Pharmacology & Therapeutics (2007), https://pubmed.ncbi.nlm.nih.gov/17429350/ ; Gieringer et al., Journal of Cannabis Therapeutics (2004) ; Pomahacova et al., International Journal of Pharmaceutics (2009) ; Blount et al., New England Journal of Medicine (2020), https://www.nejm.org/doi/full/10.1056/NEJMoa1916433 ; CDC EVALI update (2020), https://www.cdc.gov/tobacco/e-cigarettes/outbreaks/index.html
What the clinical studies found: vapor delivery, THC exposure, and carbon monoxide
The single study most often cited when people ask whether vaporized cannabis “hits the same” as smoked cannabis is Abrams et al. 2007, published in Clinical Pharmacology & Therapeutics. It matters because it did not treat vaporization as a lifestyle preference or a flavor issue. It tested a direct clinical question: can vaporization deliver THC into the bloodstream at levels comparable to smoking while reducing a clear marker of combustion exposure?
The Abrams 2007 UCSF crossover study
Abrams and colleagues ran a randomized crossover trial at the University of California, San Francisco, with 18 healthy adult cannabis users completing the protocol. A crossover design is important here. Each participant served as his or her own control, using both smoked cannabis and vaporized cannabis on separate study days rather than being assigned to only one route. That sharply reduces between-person noise from tolerance, inhalation habits, metabolism, and body size.
The study compared smoked and vaporized cannabis under controlled laboratory conditions across several dose levels, including low, medium, and high THC conditions. Participants inhaled either smoke or vapor generated from cannabis with defined potency, and the researchers tracked several outcomes that speak to both drug delivery and combustion exposure.
Those outcomes were not vague. The team measured plasma THC concentrations, subjective drug effect ratings, heart rate, and exhaled carbon monoxide (CO). That combination makes the paper unusually useful. Plasma THC tells you whether the active cannabinoid actually reached systemic circulation. Subjective effect ratings address the common user-level question of whether the psychoactive experience is comparable. Heart rate gives another physiologic marker of THC effect. Exhaled CO, though, is the key combustion marker. Carbon monoxide is produced when plant material burns; if a device is generating an aerosol without substantial combustion, CO should rise far less.
That is exactly what Abrams et al. found. Vaporization delivered THC efficiently enough to produce measurable plasma levels and noticeable drug effects, but with much lower exhaled CO increases than smoking. This is the clinical expression of the chemistry difference discussed elsewhere in the article: below combustion temperatures, you can aerosolize cannabinoids without producing the same quantity of smoke-related gases.
Delivery equivalence: similar THC effects, different combustion markers
The strongest takeaway from Abrams 2007 is not that smoking and vaporization are identical. They are not. The point is narrower and more defensible: vaporization can deliver clinically meaningful THC exposure that is broadly comparable to smoking, while avoiding much of the carbon monoxide burden that comes from burning cannabis.
That matters because one of the oldest claims against vaporization is that it somehow fails as a delivery route. Abrams et al. does not support that claim. Participants receiving vaporized cannabis showed plasma THC exposure in the same general range as when they smoked, and their subjective drug effects and heart-rate responses tracked that pharmacologic delivery. In plain language, the vapor route worked.
The carbon monoxide result is where the routes split. Smoking raised exhaled CO substantially. Vaporization did not increase it to the same degree. That is not a trivial side finding. It is direct evidence that the aerosol chemistry changed when cannabis was heated without full combustion. Carbon monoxide is one of the easiest smoke markers to measure in a clinical lab, and here it behaved exactly as combustion science predicts.
This is why the study still gets cited nearly two decades later. It answered a practical question with data: yes, vaporization can produce a real THC effect, and no, it does not have to carry the same combustion signature as smoking.
The findings also line up with earlier and later laboratory work on aerosol composition. Gieringer, St. Laurent, and Goodrich in 2004 reported that cannabis vapor contained cannabinoids with fewer pyrolytic compounds than smoke. Pomahacova, Van der Kooy, and Verpoorte in 2009 showed that controlled vaporization could recover cannabinoids efficiently at set temperatures, with problematic aromatics appearing mainly at higher settings. Abrams 2007 adds the human clinical layer: less combustion marker exposure without losing the pharmacologic endpoint people are actually seeking.
What this does and does not prove
The study is strong evidence for route efficiency under short-term laboratory conditions. It is not proof that all vaporization is safe, that all vaporizers perform equally, or that long-term respiratory risk has been settled.
Start with scale. Eighteen completers is a small sample. That is normal for intensive pharmacology studies, but it limits precision and generalizability. The participants were healthy adult cannabis users in a supervised setting, not adolescents, medically fragile patients, or people using highly variable products in uncontrolled environments.
The hardware also belongs to an earlier generation of vaporizers. Temperature control and aerosol consistency have improved in many devices since 2007, but that cuts both ways: newer devices may perform differently for better or worse depending on heater design, airflow, material form, and whether the product is dry herb or extract. Abrams studied a specific vaporization setup, not every device now sold or used.
Just as important, the trial was acute. It measured immediate pharmacokinetics and short-term effects over study sessions. It did not follow participants for years to assess chronic bronchitis symptoms, airway inflammation, or longer-term lung outcomes. For those questions, the evidence base comes from other kinds of studies, including observational respiratory data such as Earleywine and Barnwell 2007 and Van Dam and Earleywine 2010, which suggest fewer respiratory symptoms among people who vaporize rather than smoke. Useful, yes. Final proof, no.
So the clean reading of Abrams et al. is this: vaporization is capable of delivering THC effectively, with subjective and physiologic effects similar to smoked cannabis, while producing far less exhaled carbon monoxide. That directly rebuts the idea that vapor “doesn’t work.” It does not justify saying inhaled cannabis is harmless, and it does not erase differences among devices, temperatures, or product types. It shows one thing very well: when cannabis is aerosolized without being burned, users can still get THC exposure without inhaling the same level of a classic combustion gas.
References
Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL. Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther. 2007;82(5):572-578. doi:10.1038/sj.clpt.6100200. https://pubmed.ncbi.nlm.nih.gov/17429350/
Gieringer D, St Laurent J, Goodrich S. Cannabis vaporizer combines efficient delivery of THC with effective suppression of pyrolytic compounds. J Cannabis Ther. 2004;4(1):7-27. doi:10.1300/J175v04n01_02.
Pomahacova B, Van der Kooy F, Verpoorte R. Cannabis smoke condensate III: the cannabinoid content of vaporised cannabis sativa. Int J Pharm. 2009;374(1-2):146-149. doi:10.1016/j.ijpharm.2009.03.011.
Respiratory outcomes and lung health: what comparative data actually show
The respiratory case for vaporization does not rest on slogans. It rests on a simpler point: when cannabis is heated without burning, users inhale fewer products of combustion. That chemical difference should matter to lungs, and the comparative human data generally point in the expected direction. But the evidence is uneven. Short-term toxicant reduction is well supported; decades-long disease outcomes are much harder to pin down.
Earleywine and Barnwell 2007 on respiratory symptoms
The most cited observational paper here is Earleywine and Barnwell’s 2007 study, which analyzed survey data from 6,883 cannabis users. The headline finding was straightforward: people who used a vaporizer reported fewer respiratory symptoms than people who smoked cannabis only. The symptom pattern matters. This was not an abstract “felt healthier” result. The differences showed up in concrete complaints associated with airway irritation, including cough, phlegm, and chest tightness.
That does not prove that vaporization eliminates respiratory harm. It does suggest that replacing smoke with aerosol generated below the combustion range reduces day-to-day bronchitic symptoms. That is biologically plausible. Smoke contains tar, carbon monoxide, and many pyrolysis products that are either absent or markedly lower when cannabis is vaporized at controlled temperatures. If users inhale less of that mixture, fewer irritated-airway symptoms is the result one would expect.
Van Dam and Earleywine’s 2010 follow-up sharpened the picture. Using the same large survey dataset, they reported that cannabis users who had switched to vaporization showed fewer respiratory symptoms, and that the benefit became more evident as smoking exposure declined. That last point is easy to miss but important. Vaporization is not magic if smoking continues heavily alongside it. The comparison gets cleaner when smoking is actually displaced rather than merely supplemented.
These studies fit with the laboratory and clinical chemistry data. Abrams et al. 2007, in a randomized crossover study at UCSF and CPMC, found that vaporized cannabis delivered THC with similar systemic exposure to smoked cannabis while producing much smaller increases in exhaled carbon monoxide. Carbon monoxide is not the whole respiratory story, though it is a useful marker of combustion exposure. Put the pieces together and the pattern is coherent: similar cannabinoid delivery, less combustion, fewer reported respiratory symptoms.
What observational studies can and cannot establish
The weakness of the respiratory symptom literature is not that it points the wrong way. It is that most of it is observational and self-reported. Earleywine and Barnwell did not randomize people to years of smoking or years of vaporizing. They surveyed users with different habits, devices, inhalation styles, smoking histories, and tobacco exposure. That limits causal certainty.
Confounding is the first problem. Mixed tobacco use is a major one. A person who smokes cannabis and cigarettes is not comparable to a person who vaporizes cannabis and avoids tobacco, even if both are counted as cannabis users. Tobacco can drive cough, sputum production, and chronic bronchitis symptoms on its own. If studies do not fully separate that out, the cannabis route comparison gets muddy.
Self-selection is another issue. People with respiratory symptoms may be more likely to switch to vaporization in the first place. That can distort results in either direction. If symptomatic users migrate toward vaporizers, the apparent benefit of vaporization could be underestimated. If people who are already more health-conscious are also more likely to vaporize, the benefit could be overstated.
Then there is self-report. Cough and chest tightness are real outcomes, but they are still subjective reports rather than spirometry, imaging, or pathology. Symptom data matter because chronic bronchitis is largely a symptom-defined condition. Still, they are not the same as proving lower rates of emphysema, airflow obstruction, or cancer over twenty years.
So the right reading is restrained but clear. Observational studies are good at showing a consistent association: cannabis users who vaporize, especially those who replace smoking rather than adding vaporization on top, tend to report fewer respiratory symptoms. They are not strong enough to settle long-term disease risk on their own.
How smoking-related respiratory risk frames the comparison
To judge vaporization fairly, the comparison has to be smoking, not clean air. The National Academies of Sciences, Engineering, and Medicine reviewed the evidence in 2017 and concluded that there is substantial evidence of a statistical association between long-term cannabis smoking and worse respiratory symptoms and more frequent chronic bronchitis episodes. That is the anchor point. Cannabis smoke is not benign just because the literature on COPD and lung cancer is less settled than it is for tobacco.
The same NASEM review found more limited or unclear evidence for associations with obstructive lung disease and lung cancer. That uncertainty should not be stretched into a claim that smoking cannabis poses no respiratory risk. It means the strongest evidence is for chronic bronchitis-type symptoms rather than for every long-latency lung disease outcome.
Against that backdrop, vaporization looks favorable as a harm-reduction comparison. If smoking cannabis is associated with cough, sputum, wheeze, and bronchitic episodes, and vaporization lowers exposure to combustion products that plausibly drive those symptoms, then fewer respiratory complaints among vaporizer users is not surprising. It is the expected result.
The hard limit is time. Researchers have much better evidence for acute and short-term exposure differences than for decades-long lung outcomes in exclusive dry-herb vaporizer users. The comparative respiratory evidence favors vaporization over smoking. It does not justify calling inhaled cannabis harmless, and it does not erase the need to distinguish dry-herb vaporization from contaminated oil-cartridge exposures that drove EVALI. The honest position is narrower and stronger: if the alternative is smoking cannabis, the lung data and the chemistry both point in the same direction—vaporization is likely the lower-respiratory-burden route, even though the long-horizon evidence base remains incomplete.
References: Earleywine & Barnwell, 2007; Van Dam & Earleywine, 2010; Abrams et al., 2007; National Academies of Sciences, Engineering, and Medicine, 2017.
Flavor preservation, extraction efficiency, and temperature strategy
Temperature changes more than intensity. It changes which molecules leave the plant first, how completely cannabinoids are stripped from the material, and how close the device gets to the chemistry of degradation rather than controlled aerosol formation. That is why “low-temp” and “high-temp” sessions feel different even before dose is considered. The difference is not mystique. It is thermal selectivity.
Low-temperature sessions and volatile terpene retention
At the lower end of dry-herb vaporization, the aerosol usually carries a larger share of the most volatile aroma compounds relative to later, hotter draws. Terpenes such as β-caryophyllene, myrcene, limonene, and linalool are often discussed with approximate release or boiling ranges, but those numbers are not fixed truths inside actual cannabis flower. Matrix effects, moisture, pressure, and decomposition all shift real-world behavior. Even so, the general pattern holds: more volatile compounds transfer earlier, and the aerosol tends to smell brighter and taste more distinct when temperatures stay modest.
This is why low-temperature vapor is often described as lighter or cleaner. The aerosol is commonly less dense, less toasted in flavor, and less dominated by heavy late-session notes. That does not mean it is chemically pure. It means the profile is weighted toward early-releasing cannabinoids and terpenes rather than the broader mix that appears as temperature rises.
The tradeoff is incomplete extraction per puff. Lower settings usually leave behind more THC, CBD, and other less readily transferred material unless the session is extended. A patient, slower extraction can partly compensate, but low temperature by itself does not guarantee efficiency.
Higher temperatures and fuller extraction
As temperatures climb, cannabinoid yield per draw usually increases. More of the resinous content is mobilized, the aerosol gets thicker, and the plant material is more fully exhausted. Controlled studies support this temperature-dependent story. Pomahacova, Van der Kooy, and Verpoorte (2009) found substantial cannabinoid recovery during vaporization at 210°C, while signs of unwanted aromatic byproducts appeared at the highest settings tested. That is the useful boundary: hotter settings can improve extraction, but they also narrow the margin before overheating.
Flavor often falls off before cannabinoids do. A hotter session may deliver more THC in fewer draws, yet the original terpene expression becomes flatter, roasted, or simply absent because those compounds have already been driven off or degraded. Users commonly interpret this as stronger vapor. Sometimes it is. Sometimes it is just denser aerosol with less aromatic complexity.
Device mechanics matter here as much as the displayed number. A loosely packed chamber allows better airflow and more even extraction. An overly fine grind can increase resistance, create hot spots, and push local temperatures above the set point. Draw speed matters too: fast inhalation can cool the heater or herb bed, while a very slow draw can let certain devices overshoot and darken the load. Conduction-heavy systems are especially prone to uneven heating if packing is tight or stirring is neglected; convection tends to be more uniform but still depends on airflow.
Why harsher aerosol is often a chemistry signal
Harshness is not just “more vapor.” It is often evidence that the aerosol chemistry has shifted. As temperature rises, terpene degradation, plant-matrix breakdown, and near-pyrolytic reactions become more likely. Controlled vaporization still differs sharply from smoke; Abrams et al. (2007) showed comparable THC delivery with far less exhaled carbon monoxide than smoking, which is exactly what you would expect when combustion is avoided. But “not smoke” does not mean “nothing irritating is present.”
When vapor becomes scratchy, bitter, or singed, that often signals more than throat sensitivity. It may reflect hotter, drier aerosol, loss of volatile flavor compounds, and growing contributions from degradation products. In practice, people often read low-temperature vapor as cleaner because it contains fewer of those late-stage signals, while high-temperature sessions feel heavier because extraction is fuller and the chemistry is edging closer to thermal damage. The line is not only temperature. It is temperature plus time, airflow, grind, moisture, and heater stability. Those variables decide whether a session stays in the vaporization zone or drifts toward charring.
Desktop versus portable vaporizers
The useful distinction here is not “home device” versus “travel device.” It is thermal engineering. A vaporizer changes chemistry only if it can keep plant material in a narrow temperature window where cannabinoids and terpenes are released while pyrolysis stays limited. By that standard, desktop systems usually have an advantage because they have larger heaters, steadier power delivery, and less aggressive battery-management compromise.
Thermal stability and reproducibility
Desktop units tend to hold set temperature more accurately during a draw. That matters because inhalation is a cooling event: air rushes past the heater and through the cannabis bed, pulling heat out of the system. A weak heater or slow control loop drops below target, then overshoots while recovering. The result is hot/cool cycling rather than stable aerosol generation.
That cycling is not a minor comfort issue. It changes which compounds transfer into the aerosol and when. Lower-than-intended temperatures may favor lighter terpenes and leave cannabinoids behind. Overshoot can push parts of the load into local thermal degradation, especially in conduction-heavy ovens where herb contacts hot walls directly. Desktop designs, particularly those with stronger convection heaters or larger thermal mass, are generally better at minimizing those swings over repeated inhalations.
This is the right way to think about reproducibility. If two sessions begin at the same nominal setting but one device sags 20–30°C during each draw while another recovers almost immediately, they are not chemically equivalent sessions even if the display shows the same number.
Power constraints and session consistency
Portable units live within battery limits. That affects heater wattage, warm-up reserve, and sustained output over a full session. As battery charge drops, some devices reduce available power or become slower to recover between inhalations. Long draws, tightly packed material, or rapid back-to-back puffs can expose those limits.
Desktop devices, powered from the wall, usually maintain airflow and heat delivery more consistently across larger loads and longer sessions. That improves repeatability from first inhalation to last. Portables can still work well, but they more often require technique compensation: slower draws, pauses between pulls, smaller chambers, or higher set temperatures to offset cooling. Once user technique becomes part of temperature control, reproducibility falls.
When form factor changes chemistry
Form factor matters when it alters actual heater behavior enough to change aerosol composition. A stable device is more likely to produce predictable cannabinoid extraction with lower combustion-related byproducts. A struggling device may underextract at first, then char edges or hotspots later. That does not mean portable equals harmful or desktop equals clean. It means temperature control, heater reserve, and airflow design have chemical consequences.
The broader evidence on vaporization versus smoking points in this direction. Abrams et al. (2007) found vaporized cannabis delivered THC similarly to smoked cannabis with much smaller increases in exhaled carbon monoxide, a combustion marker. That advantage depends on real vaporization conditions being maintained. If a device cannot control heat well, the gap narrows. Desktop units usually do better at preserving that gap because they are built around thermal stability, not mobility.
Dosing differences versus smoking
Many people report that they need less cannabis in a vaporizer than in a joint or pipe to reach a similar effect. That perception is plausible, but it is not a fixed law of pharmacology. Vaporization can reduce waste and change delivery. It does not turn cannabis dosing into an exact science.
Why vaporization can feel more efficient
The simplest reason is sidestream loss. A lit joint keeps burning between puffs, sending cannabinoids and combustion products into the air whether the user is inhaling or not. A vaporizer only generates substantial aerosol during active heating and airflow, so less material is lost passively between draws. That alone can make the same amount of flower feel like it “goes further.”
There is also a chemistry reason. When cannabis is vaporized below combustion temperatures, more of the inhaled aerosol consists of cannabinoids and terpenes rather than smoke from burning plant matter. Laboratory studies have found that vapor can deliver cannabinoids with fewer pyrolytic byproducts than smoke under controlled conditions (Gieringer, St. Laurent & Goodrich, 2004; Pomahacova, Van der Kooy & Verpoorte, 2009). Clinically, Abrams et al. (2007) showed that vaporized and smoked cannabis could produce comparable plasma THC exposure and subjective drug effects, while exhaled carbon monoxide rose much less with vaporization. That matters here: equivalent effect is possible without implying identical delivery mechanics.
Users often feel this as “stronger per gram,” but that phrase hides a lot of variation. Some vaporizers extract cannabinoids very effectively. Some do not. Temperature, airflow, and heating uniformity matter. Convection-heavy designs may extract more evenly than devices that create local hot spots, and poor technique can leave active compounds behind in the spent material.
Pulmonary absorption, sidestream loss, and puff behavior
Inhaled cannabinoids act quickly because the lungs provide a large absorptive surface and rapid access to the bloodstream. Vapor shares that rapid onset with smoke. New users should still start low, because inhaled vapor can come on within minutes.
The route may be the same, but the puffing pattern often differs. Smoking a joint usually involves repeated puffs to keep it lit. Vaporization allows slower, more deliberate inhalation, and some people find that easier to titrate. A controlled draw can improve aerosol formation and reduce the tendency to cough away part of the dose. Breath-hold behavior also changes delivery, though not always as much as users think; long holds add discomfort and are not a reliable way to standardize dose.
This is where Abrams et al. (2007) is useful. The study does not prove that vaporization always delivers more THC than smoking. It shows that, under controlled conditions, vaporization can achieve similar systemic exposure and subjective effects. Pharmacokinetics still depend on route plus technique: puff duration, inhalation depth, interval between puffs, and the temperature profile of the device.
Why equal grams do not mean equal delivered dose
A gram is only the starting mass. It is not the delivered dose. Two people can use the same weight of cannabis and absorb very different amounts of THC.
THC content is the obvious variable, but not the only one. Chamber loading changes airflow and extraction. Grind size changes surface area. Moisture content changes how readily cannabinoids transfer into aerosol. Temperature matters a great deal: lower settings may preserve flavor but leave more cannabinoids behind, while higher settings usually extract more aggressively at the cost of more thermal degradation. Puff speed matters too. Draw too hard and some devices cool down or pull air past the material unevenly. Draw too softly and extraction may remain incomplete.
Smoking has the same problem, only with added losses from constant combustion and sidestream smoke. So equal grams across the two routes do not mean equal absorbed dose, equal plasma THC, or equal effect. Vaporization can be more materially efficient under some conditions, and many users experience it that way. Still, “less flower, same effect” should be treated as a common outcome, not a guaranteed rule.
References: Abrams et al., 2007, Clinical Pharmacology & Therapeutics (https://pubmed.ncbi.nlm.nih.gov/17429350/); Gieringer, St. Laurent & Goodrich, 2004, Journal of Cannabis Therapeutics; Pomahacova, Van der Kooy & Verpoorte, 2009, International Journal of Pharmaceutics (https://pubmed.ncbi.nlm.nih.gov/19379825/).
EVALI and the cartridge problem: why this crisis does not map neatly onto dry-herb vaporization
The EVALI outbreak changed public discussion of inhaled cannabis almost overnight, but it also flattened important distinctions. “Vaping” became a catch-all term for very different exposures: nicotine e-liquids, THC oil cartridges, and dry-herb cannabis vaporization. Chemically, those are not the same thing. The 2019 outbreak was not evidence that heating cannabis flower below combustion suddenly causes the same injuries seen with contaminated oil cartridges. It was, far more specifically, a contamination and formulation disaster centered on illicit THC liquids.
What EVALI was
EVALI stands for e-cigarette, or vaping, product use-associated lung injury. The U.S. outbreak peaked in 2019 and led to a large national investigation by the CDC, FDA, state health departments, and clinical researchers. In its final outbreak update, the CDC reported 2,807 hospitalized EVALI cases or deaths as of February 18, 2020, including 68 confirmed deaths across 29 states and the District of Columbia (CDC, 2020).
Clinically, EVALI was not a subtle irritation syndrome. Many patients presented with severe respiratory symptoms, hypoxemia, chest pain, gastrointestinal symptoms, and constitutional complaints such as fever and fatigue. Imaging often showed bilateral pulmonary infiltrates. Some patients required intensive care, mechanical ventilation, or died. That severity matters, because it points away from a vague “vapor is bad” explanation and toward a specific toxic exposure.
From the start, case interviews showed a strong association with THC-containing cartridges, especially products obtained from informal or illicit sources. Not every patient reported the same pattern of use, and early surveillance had to work through incomplete histories, mixed-product use, and inconsistent labeling. Still, the center of gravity became clear: the outbreak clustered around cartridge-based inhalation of oil formulations, not around people vaporizing dried cannabis flower.
That distinction is the one many headlines blurred. Dry-herb vaporization heats plant material to release cannabinoids and terpenes into an aerosol while aiming to stay below combustion. Cartridge products aerosolize a processed liquid or semi-liquid extract whose safety depends not only on temperature, but on what was dissolved in it, diluted into it, or contaminated it. Different matrix, different toxicology.
Vitamin E acetate and illicit THC cartridges
The strongest evidence on cause came from chemical analysis of patient samples. In a landmark New England Journal of Medicine paper, Blount et al. (2020) reported that vitamin E acetate was detected in bronchoalveolar lavage fluid from 48 of 51 EVALI patients, but not in fluid from the healthy comparator group studied. That finding aligned with CDC laboratory work and with the epidemiology pointing toward illicit THC cartridges.
Vitamin E acetate is an oil-like diluent. It had been used as a thickening agent in some illicit THC cartridges, apparently to alter viscosity and appearance. That made economic sense for counterfeit supply chains. It made toxicological sense as a disaster. A substance can be acceptable in foods or topical products and still be unsafe when inhaled into the lungs as an aerosolized oil. Route of exposure matters.
This does not mean vitamin E acetate explained every single case on its own, or that all cartridges implicated in EVALI contained identical chemistry. The CDC was careful about that. Other toxicants may have contributed in some patients, and device temperatures, coil conditions, and extract composition likely shaped what users inhaled. But vitamin E acetate became the leading causal suspect for good reason: it appeared repeatedly in patient lung samples and fit the outbreak pattern.
Just as important is what the evidence did not show. It did not show that dry-herb vaporization caused EVALI. Flower vaporizers do not use vitamin E acetate as a diluent because there is no oil formulation to dilute. They heat cannabis plant material. The chemistry of concern there is overheating, local charring, and thermal degradation products, not adulterated lipid-like additives hiding in a cartridge.
That is the major correction to common memory of 2019. EVALI was not “proof that all cannabis vaping is dangerous in the same way.” It was proof that inhaling contaminated illicit oil products can produce catastrophic lung injury.
The reporting mistake: treating all vaporization as one exposure
Public messaging often collapsed three categories into one: nicotine e-cigarettes, THC cartridges, and dry-herb vaporizers. Once that happened, “vaping” sounded like a single act with a single risk profile. It is not. Exposure science does not work that way.
If someone smokes cannabis flower, the dominant chemistry includes combustion products such as carbon monoxide, tar, soot, and polycyclic aromatic hydrocarbons. If someone vaporizes dry herb with controlled temperatures, those combustion products fall sharply or may be absent at proper settings, though overheating can still generate irritants and decomposition compounds. If someone uses a cartridge, risk depends heavily on extract purity, additives, hardware behavior, and thermal byproducts from the liquid itself. Those are related topics, but not interchangeable ones.
That is why EVALI should not be used as a blanket argument against dry-herb vaporization. It also should not be twisted into a blanket defense of all concentrates. The right reading is narrower and more useful: the outbreak mechanism was tied primarily to adulterated THC oil cartridges, especially illicit ones, rather than to the basic act of heating cannabis below combustion.
That narrower reading fits the rest of the evidence in this article. Clinical and laboratory studies on dry-herb vaporization, including Abrams et al. (2007), Gieringer et al. (2004), and Pomahacova et al. (2009), support a lower-combustion exposure profile than smoking when temperatures are controlled. None of that makes inhalation harmless. It does mean EVALI should be filed under contaminant toxicology, not treated as a refutation of the combustion-versus-vaporization distinction.
References: CDC (2020); Blount et al., New England Journal of Medicine (2020).
Where the evidence is strong, where it is weak, and what readers should actually take from it
What is well supported
The strongest evidence supports a narrow claim, not a sweeping one: for inhaled cannabis, controlled dry-herb vaporization generally reduces exposure to combustion toxicants relative to smoking while still delivering THC efficiently. That position rests on both chemistry and human data. When cannabis is heated below the point of burning, aerosol generation shifts away from full combustion and toward cannabinoids, terpenes, and lower amounts of pyrolytic byproducts. Lab studies by Gieringer, St. Laurent, and Goodrich (2004), Pomahacova, Van der Kooy, and Verpoorte (2009), and Lanz et al. (2016) all point in that direction, with lower carbon monoxide and fewer smoke-associated toxicants than combusted cannabis under controlled conditions.
Abrams et al. (2007) is still one of the cleanest clinical demonstrations. In that randomized crossover trial, 18 adults completed smoked and vaporized cannabis sessions at matched potency conditions. Plasma THC exposure and subjective effects were broadly comparable, but exhaled carbon monoxide rose much less with vaporization than with smoking. That matters because carbon monoxide is a direct marker of combustion exposure, not a vague proxy.
The respiratory-symptom literature also leans in the same direction, though it is weaker than the chemistry. Earleywine and Barnwell (2007), using a large survey sample of 6,883 cannabis users, reported fewer respiratory symptoms among people who vaporized than among those who only smoked. Van Dam and Earleywine (2010) found similar patterns in users who had switched to vaporization.
Reduced exposure, though, is not the same as harmless exposure. Aerosols can still contain irritants, and higher temperatures can increase degradation products. “Less smoke chemistry” is the defensible claim.
What remains uncertain
The weak spots are real. Long-term prospective lung data are sparse. We have far better evidence on immediate aerosol chemistry than on what decades of regular dry-herb vaporizer use do to lung function, airway inflammation, or chronic symptoms independent of prior smoking history.
Device variability is another problem. “Vaporizer” is not one chemically uniform category. Heating mode, temperature control, airflow, herb moisture, draw speed, and hot-spot formation all change what ends up in the aerosol. A tightly regulated desktop unit and a poorly controlled portable device can behave very differently.
Internet temperature charts are also less trustworthy than they look. Popular lists present cannabinoid and terpene boiling points as fixed truths, but real cannabis does not behave like a jar of isolated pure compounds under one pressure condition. Transfer, evaporation, and decomposition overlap. The useful way to read those numbers is as approximate release ranges, not exact switch points.
Legal and health context
Health discussions around vaporization often get distorted by mixing together dry herb, concentrates, nicotine e-cigarettes, and illicit THC cartridges. That is how misinformation spreads. The EVALI outbreak did not show that all cannabis vaporization causes the same risk; CDC investigations and Blount et al. (2020) tied the outbreak primarily to vitamin E acetate in illicit THC cartridges, finding it in bronchoalveolar-lavage fluid from 48 of 51 patients and in none of the healthy comparators studied.
That distinction should not be softened. Dry-herb vaporization and contaminated oil cartridges are different exposure scenarios.
The legal side is also uneven: cannabis laws vary widely by jurisdiction, and the legality of possession, use, or devices can differ even where medical or adult-use cannabis exists. Readers should come away with one durable point. When discussing cannabis vaporization, chemistry, hardware design, and product type must be kept separate. If they are collapsed into a single question, the result is not caution. It is confusion.